


Development of the Oncolytic Virus, CF33 and its Derivatives for Peritoneal-Directed Treatment of Gastric Cancer Peritoneal Metastases



Authors

Annie Yang, Zhifang Zhang, Shyambabu Chaurasiya, Anthony K. Park, Audrey Jung, Jianming Lu, Sang-In Kim, Saul Priceman, Yuman Fong, Yanghee Woo

Correspondence

yhwoo@coh.org, zh Zhang@coh.org

In Brief

CF33-OVs demonstrate robust in vitro and in vivo antitumor effects in GCPM models. Intraperitoneal delivery of CF33-hNIS-antiPDL1 leads to tumor regression and prolonged animal survival in a xenograft GCPM mouse model.